Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease-Reference-Cited by-同舟云学术

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

Published:2002-09 Issue:9 Volume:97 Page:2357-2363
ISSN:0002-9270
Container-title:The American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterology

Author:

Vermeire Severine,Louis Edouard,Carbonez An,Assche Gert,Noman Maja,Belaiche Jacques,Vos Martine,Gossum Andre,Pescatore Paul,Fiasse Rene,Pelckmans Paul,Reynaert Hendrik,D'Haens Geert,Rutgeerts Paul

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference18 articles.

1. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

2. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)

3. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

4. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

5. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of early remission after infliximab in Crohn’s disease using baseline microbiome and metabolomics;Journal of Pharmaceutical and Biomedical Analysis;2024-12

2. CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn’s disease;Insights into Imaging;2024-03-13

3. Autoimmune Haemolytic Anaemia as a Rare and Potentially Serious Complication of Crohn’s Disease in a 11-Year-Old Child—Case Report and Minireview;Children;2023-10-17

4. The importance of predicting patient responses to monoclonal antibodies for Crohn’s disease;Expert Opinion on Biological Therapy;2023-08-30

5. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review;World Journal of Gastroenterology;2023-08-07